Foghorn therapeutics to participate in cowen's 44th annual health care conference

Cambridge, mass., feb. 28, 2024 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in cowen's 44th annual health care conference, which is taking place on march 4–6, 2024, at the boston marriott copley place in boston, ma. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking